Graves Disease (Basedow's Disease)
2
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Atorvastatin
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
50%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
Research Network
Common Treatments
- Atorvastatin1
- The Early Prophylactic Introduction Of Low Dose Of Lt4 50 Μgd At 15 Days Postablation1
- The Initiation Of Lt4 As Soon As The First Biological Signs Of Hypothyroidism1
Active Sponsors
- Assistance Publique Hopitaux De Marseille1
- Region Skane1
Top Investigators
Assistance Publique hôpitaux de Marseille
Region Skåne, Endokrinologimottagning
Related Conditions
- Graves Disease1
- Graves Ophthalmopathy Go1
- Graves Ofthalmopathy1
- Graves Hyperthyroidism1
- Thyroidassociated Ophthalmopathy1